

Anti-inflammatory IgG Production Requires Functional P1 Promoter in β -Galactoside α 2,6-Sialyltransferase 1 (ST6Gal-1) Gene^{*[5]}

Received for publication, January 24, 2012, and in revised form, March 8, 2012. Published, JBC Papers in Press, March 15, 2012, DOI 10.1074/jbc.M112.345710

Mark B. Jones[‡], Mehrab Nasirikenari[‡], Amit A. Lugade[§], Yasmin Thanavala[§], and Joseph T. Y. Lau^{‡1}

From the Departments of [‡]Molecular and Cellular Biology and [§]Immunology, Roswell Park Cancer Institute, Buffalo, New York 14263

Background: β -Galactoside α 2,6-sialyltransferase 1 (ST6Gal-1) action is essential for the anti-inflammatory activity in intravenous immunoglobulin (IVIG) therapy.

Results: Fc sialylation changes in accordance to the severity of inflammation. Inactivation of the P1 promoter abrogated IgG Fc sialylation.

Conclusion: Fc sialylation depends on ST6Gal-1 in the circulation. Defective Fc sialylation is a mechanism for the generally proinflammatory tendencies of the P1-ablated mutant mouse (*Siat1* Δ P1).

Significance: Anti-inflammatory bioactivity of IVIG requires sialylated Fc.

The anti-inflammatory properties associated with intravenous immunoglobulin therapy require the sialic acid modification of the *N*-glycan of the Fc domain of IgG. Sialylation of the Fc fragment is mediated by β -galactoside α 2,6-sialyltransferase 1 (ST6Gal-1), acting on the Gal(β 4)GlcNAc terminal structure of the biantennary *N*-glycans on the Fc domain. However, little is known regarding the *in vivo* regulation of Fc sialylation and its role in the progression of inflammatory processes. Here, we report that decreased Fc sialylation of circulatory IgG accompanies the acute phase response elicited by turpentine exposure or upon acute exposure to either nontypeable *Haemophilus influenzae* or ovalbumin. However, Fc sialylation was increased 3-fold from the base line upon transition to chronic inflammation by repeated exposure to challenge. The P1 promoter of the ST6Gal-1 gene is critical for Fc sialylation, but P1 does not drive ST6Gal-1 expression in B cells. The *Siat1* Δ P1 mouse, with a dysfunctional P1 promoter, was unable to produce sialylated Fc in the systemic circulation, despite the presence of Gal(β 4)GlcNAc termini on the Fc glycans. The major contribution of P1 action is to synthesize ST6Gal-1 enzymes that are deposited into the systemic circulation. The data strongly indicate that this pool of extracellular ST6Gal-1 in the blood impacts the sialylation of IgG Fc and that defective Fc sialylation is likely a major contributing mechanism for the proinflammatory tendencies previously noted in *Siat1* Δ P1 animals.

Large-dose intravenous immunoglobulin (IVIG)² therapy is widely used to treat autoimmune syndromes, including lupus

erythematosus and rheumatoid arthritis, and to restore platelet counts in immune-related thrombocytopenia (1, 2). The effectiveness of IVIG therapy in significantly reducing mortality in a humanized xenogeneic model of graft-versus-host disease in NOD/SCID/ γ c[−] mice has also been demonstrated recently (3), although the effectiveness as a prophylactic therapy for hematopoietic stem cell transplantation remains controversial (4–6). The anti-inflammatory property associated with IVIG has an absolute requirement for the sialylation of the single biantennary *N*-glycan at Asn-297 on the Fc region of IgG, which induces the expression of inhibitory Fc receptors (Fc γ RIIB) (7, 8) via a complex signaling pathway starting with DC-SIGN on dendritic cells or SIGN-R1 on splenic macrophage in mice (7, 9). Sialylated Fc structures (Sia-Fc) are present in 2–4% of IgG in normal human circulation (8) and are generated by the addition of terminal α 2,6-linked (but not α 2,3-linked) sialic acids. β -Galactoside α 2,6-sialyltransferase 1 (ST6Gal-1) mediates construction of α 2,6-sialyl linkages on *N*-glycans and is directly responsible for generation of the anti-inflammatory effects of IVIG (10).

Our laboratory has demonstrated that ST6Gal-1 deficiency results in a generally proinflammatory state; mice with genetically induced ST6Gal-1 deficiency exhibit exaggerated acute peritonitis and Th2 pulmonary inflammation (11, 12). This phenotype was attributed specifically to the inactivation of the liver-specific promoter P1, one of six promoters regulating tissue- and cell-specific transcription of the ST6Gal-1 gene (13–15). Inactivation of P1 results in decreased ST6Gal-1 released into the systemic circulation but no appreciable alteration in the extent of sialylation of circulatory glycoproteins released into the blood by the liver (16). P1-mediated ST6Gal-1 expression in the liver is also regulated in inflammation (15, 17). Although P1 is not believed to be involved in ST6Gal-1 expression in B cells (14), here, we report the surprisingly absolute

^{*} This work was supported, in whole or in part, by National Institutes of Health Grants R01AI38193 and P01HL107146 (to J. T. Y. L.) and R01 AI069379 (to Y. T.). The core facilities used in this work were supported in part by National Cancer Institute Cancer Center Support Grant CA16056 to the Roswell Park Cancer Institute.

^[5] This article contains supplemental Fig. 1.

¹ To whom correspondence should be addressed: Dept. of Molecular and Cellular Biology, Roswell Park Cancer Institute, Elm and Carlton St., Buffalo, NY 14263. Tel.: 716-845-8914; E-mail: joseph.lau@roswellpark.org.

² The abbreviations used are: IVIG, intravenous immunoglobulin; Sia-Fc, sialylated Fc; ST6Gal-1, β -galactoside α 2,6-sialyltransferase 1; NTHi, nontypeable *H. influenzae*; OVA, ovalbumin; SNA, *S. nigra* agglutinin; PSL, *P. squamosus* lectin; ECL, *E. crista-galli* lectin.

requirement for the P1 promoter in Sia-Fc production. Targeted ablation of the P1 region in *Siat1* Δ P1 mice that results in attenuated liver and circulatory ST6Gal-1 levels but normal expression elsewhere (17); these mice do not express Sia-Fc in their circulatory IgG. The data are highly suggestive of a role for the circulatory pool of ST6Gal-1 originating from P1-mediated transcription in the sialylation of the Fc region. This mechanism may explain the generally proinflammatory tendencies of animals with ST6Gal-1 deficiencies.

EXPERIMENTAL PROCEDURES

Animals and Models of Inflammation—Mouse strains C57BL/6 (from JAX®), *Siat1* Δ P1, and *Siat1*-null were as described previously (17, 18). For the turpentine model of sterile acute phase response, 100 μ l of turpentine was injected subcutaneously into the scruff of the neck. The mice were killed, and sera were collected via terminal heart puncture at the following points: before injection (base line) and 72 h after turpentine treatment. The nontypeable *Haemophilus influenzae* (NTHi) model of chronic pulmonary inflammation was performed as described earlier (19–21). Briefly, mice received biweekly oropharyngeal instillations of 1×10^6 colony-forming units of live NTHi strain 1479 for 16 consecutive weeks. Blood samples were taken weekly by retro-orbital bleed. For induction of acute allergic airway inflammation by ovalbumin (OVA), mice were sensitized by two intraperitoneal injections of 20 μ g of OVA (grade IV, Sigma) adsorbed to 2.25 mg of Imject alum ($\text{Al}(\text{OH})_3$ - $\text{Mg}(\text{OH})_2$, Pierce) in 100 μ l of saline on days 0 and 14. Mice were challenged on days 24, 25, 26, and 27 with 20-min inhalations of an aerosol generated by nebulization of a 1% OVA solution prepared in saline. Mice were killed by intraperitoneal injection of 1 ml of Avertin (2.5 g of 2,2,2-tribromethanol and 5 ml of 2-methyl-2-butanol in 200 ml of sterile deionized water) on day 29. For induction of chronic allergic airway inflammation by OVA, mice were sensitized as per the acute model but challenged by OVA nebulization for 2 consecutive days every other week for 3 months (days 28 and 29, 42 and 43, 56 and 57, 70 and 71, 84 and 85, and 98 and 99) and killed on day 101. In both allergy models, bronchoalveolar lavage was performed. The thoracic cavity was opened to expose the trachea, which was cannulated with a 22-gauge intravenous catheter. PBS (750 μ l) was injected and withdrawn from the lung two times using a tuberculin syringe. A white blood cell count of the bronchoalveolar lavage fluid was performed using a Z2 COULTER COUNTER (Beckman). The Roswell Park Cancer Institute Animal Care and Use Committee approved all animal studies presented here.

Isolation and Analysis of Fc Regions of Circulatory IgG—Protein A-agarose beads (Sigma) were washed three times with wash buffer (10 mM Tris and 0.1% Nonidet P-40, pH 7), resuspended in wash buffer at the initial volume, and added to an equal volume of serum (50 μ l) pooled from five animals. Samples were then shaken vigorously for 90 min at room temperature before being washed three times with wash buffer. The remaining protein A beads were resuspended in elution buffer (0.1 M glycine, 0.1 M sodium acetate, and 5 mM MgCl_2 , pH 3.5) equal to the volume of the original serum sample and shaken at room temperature for 10 min. After incubation, samples were

immediately spun down, and the supernatant was drawn off and adjusted to pH 7 with an equal volume of neutralization solution (0.1 M HEPES, 5 mM MgCl_2 , and 50 mM NaCl, pH 12) to reach pH 7. Immobilized papain-agarose beads (Pierce) were washed three times with digest buffer (20 mM cysteine, 20 mM sodium phosphate, and 10 mM EDTA, pH 7), resuspended in digest buffer at the initial volume, and added to IgG preparations at a 1:2 ratio. Samples were shaken at room temperature for 24 h and then briefly spun down, and the supernatant containing the Fc fragments was removed.

For Western blot analysis of Fc fragments, samples were separated by either 10 or 12% SDS-PAGE and transferred to a PVDF membrane (Millipore). Fc fragment gels were loaded to equalize the Fab signal (typically, 10 μ l of digested IgG). Blots were blocked in TBS/Tween containing 5% BSA for 1 h at room temperature or overnight at 4 °C. Lectin probes used are as follows. *Sambucus nigra* agglutinin (SNA)-biotin (Vector Laboratories) at a working concentration of 0.08 μ g/ml or *Polyporus squamosus* lectin (PSL; EY Laboratories) at 2.5 μ g/ml was used for the detection of α 2,6-sialic acids, and *Erythrina cristagalli* lectin (ECL)-biotin (Vector Laboratories) at 5 μ g/ml was used for the detection of terminal galactose. Lectin blots were subsequently incubated with streptavidin-Cy5 (GE Healthcare) at 1:1000 or streptavidin-DyLight 649 (Jackson ImmunoResearch Laboratories) at 1:2000. After lectin binding, Fc fragment blots were incubated with goat anti-mouse Fc-Cy3 and goat anti-mouse Fab-Cy2 (Jackson ImmunoResearch Laboratories) at 1:1000. Fluorescent blots were visualized on a Typhoon Trio (GE Healthcare) and quantified with ImageQuant.

Sample Preparation and Release of N-Linked Glycans for Glycomics—Fc fragments were recovered by preparative SDS-PAGE. All bands between 26 and 34 kDa in each sample gel were extracted by slicing carefully with a scalpel blade, cut into \sim 1-mm squares, and transferred into prerinsed screw-cap glass tubes. The gel pieces were destained by alternate addition/exchange of 50 mM ammonium bicarbonate and acetonitrile, which was repeated at least five times until the gels turned clear. After destaining, the gel slices were reswelled with 50 mM ammonium bicarbonate (previously chilled at 4 °C) and allowed to set at 4 °C for 45 min before adding peptide:N-glycosidase F. The enzyme-treated gels were placed in a heating block (37 °C) overnight. The released N-linked glycans were extracted in series with 20% acetonitrile in 5% formic acid, 50% acetonitrile in 5% formic acid, and 80% acetonitrile in 5% formic acid. Each extraction step was accomplished by allowing the gel in extractant solution to set for at least 25 min. The acetonitrile was evaporated under a stream of nitrogen gas, and the extracts were eventually lyophilized. Prior to per-O-methylation, the eluates were passed through a Sep-Pak C_{18} cartridge (Waters) for purification. The N-linked glycans were permethylated for structural characterization by mass spectrometry. Briefly, the dried eluates were dissolved with dimethyl sulfoxide and methylated with NaOH and methyl iodide. The reaction was quenched with water, and per-O-methylated carbohydrates were extracted with methylene chloride and dried under N_2 . For profiling by MALDI-TOF-MS, the permethylated glycans were dissolved with methanol and crystallized with α -dihy-

droxybenzoic acid matrix (20 mg/ml in 50% methanol/water). Analysis of glycans present in the samples was performed in the positive ion mode by MALDI-TOF/TOF-MS using an AB SCIEX TOF/TOF 5800 system (Applied Biosystems/MDS Analytical Technologies). For analysis by linear ion trap-MS, the remainder of each of the permethylated *N*-linked glycans was diluted with 1 mM NaOH in 50% methanol. Each of the prepared samples was infused directly into an LTQ Orbitrap Discovery mass spectrometer (Thermo Scientific) at a flow rate of 0.5 μ l/min to obtain nanospray ionization. The full mass spectrum of each sample was obtained in the positive ion mode. MS/MS analysis of selected parent ions and total ion mapping were performed at 2-mass unit interval.

RESULTS

Sia-Fc Is Decreased in Acute Phase But Increased during Chronic Phases in Mouse Models of Pulmonary Inflammation—To quantify Fc sialylation, we developed a multichannel immunofluorescence Western blot method that permits simultaneous detection of signals from three different fluorescent probes using a tri-laser scanner (Typhoon Trio). We quantified Fc and Fab regions using anti-mouse Fc and anti-mouse Fab antibodies, respectively, and glycan structures were probed with SNA or ECL to visualize the presence of α 2,6-sialic acids or the exposed underlying disaccharide structure (Gal(β 4)GlcNAc), respectively. In combination, these three channels allowed quantification of the relative sialylation levels of Fc and Fab.

Lungs of smokers with chronic obstructive pulmonary disease are frequently colonized with NTHi strains during exacerbations (22). This colonization (with constant bacterial turnover) is akin to a low-grade smoldering infection that induces chronic airway inflammation and augments the inflammatory effects of tobacco smoke. We utilized a murine model of chronic obstructive pulmonary disease-like pulmonary inflammation to examine the extent of Fc sialylation. Repeated exposure of C57BL/6 mice to NTHi elicited chronic pulmonary inflammation highlighted by the accumulation of immune cells and proinflammatory cytokines in the airways. In this study, we measured the levels of serum Sia-Fc in NTHi-challenged mice. IgG was isolated from base-line and post-challenge serum samples. Proteolyzed Fc and Fab fragments were assayed on multichannel Western blots (Fig. 1). The overall IgG levels, as well as SNA reactivity against the Fc fragment (Fig. 1, *inset*), increased steadily over the 16-week course of repeated NTHi exposure. When expressed as SNA/Fc signal ratios, the degree of α 2,6-sialylation of the Fc fragments also increased steadily, with a maximum signal at 12 weeks of chronic NTHi exposure. Interestingly, compared with the basal SNA/Fc ratio (Fig. 1, *dashed line* denoted *Resting*), the early phases of NTHi exposure showed dramatically suppressed α 2,6-Fc sialylation. This was followed by a gradual restoration of Sia-Fc, such that circulatory Sia-Fc peaked at 12 weeks with close to a 3-fold elevation compared with the base line.

Regulation of circulatory Sia-Fc in a pulmonary Th2 inflammation model mimicking allergic asthma was also examined using OVA-sensitized (primed) mice subjected to short-term or long-term exposure to aerosolized OVA. This is summarized in Fig. 2 as either the raw tri-probe data (A) or ratios of lectin




FIGURE 1. Circulatory Fc sialylation in NTHi-mediated pulmonary inflammation. C57BL/6 mice (WT) were subjected to biweekly intra tracked instillations of NTHi for 16 consecutive weeks as detailed under "Experimental Procedures," and serum ($n = 5$) was harvested weekly and pooled (where D1 represents a post-challenge blood draw on the first day of treatment). Fc fragments of IgG were isolated from each of the weekly pools, subjected to SDS-PAGE, and probed with SNA (green), anti-Fc antibody (blue), and anti-Fab antibody (red) as displayed in the *inset*. The SNA reactivity of the Fc fragments is expressed as a ratio of the relative SNA to anti-Fc signals, where *untreated* denotes the ratio found in the serum IgG of animals without treatment.

reactivity to Fc (B). As with the NTHi-induced pulmonary response, the OVA-induced pulmonary response elicited strikingly higher Fc sialylation (expressed as SNA/Fc ratios) in WT mice after long-term repeated allergen exposure (chronic) compared with short-term allergen exposure (acute) or no exposure (primed but not challenged). Interestingly, Sia-Fc increased slightly despite allergen removal for 2 weeks after acute allergen challenge (resolution). ECL was used to assess the availability of exposed galactose termini on Fc that serve as acceptor substrate for α 2,6-sialylation. In WT animals, exposed galactose termini on Fc (expressed as ECL/Fc ratios) increased strikingly during the resolution phase after acute challenge, and the availability of exposed galactose was not further increased significantly upon chronic allergen exposure. The data indicate a two-step process in Fc sialylation during exposure of WT animals to inflammatory challenge: acute challenge led to increase production of galactose termini, whereas continued conversion of these termini to sialylated structures was less pronounced, as observed in the acute resolution phase. Then, as the inflammation progressed into the chronic stages, increased ST6Gal-1-mediated conversion into sialylated structures was observed.

In a separate model of systemic inflammation elicited by the subcutaneous instillation of the sterile irritant turpentine, WT mice responded within 72 h not only with depressed circulatory IgG but also with a 8.3-fold decreased sialylation of the Fc glycans (Fig. 3). Decreased sialylation is consistent with the decreased Sia-Fc noted in the acute stages of NTHi-elicited pulmonary inflammation models (Fig. 1). Decreased Sia-Fc was not noted in the acute OVA-induced Th2 response (Fig. 2), but that might have been due the initial priming or sensitizing step, which altered the Sia-Fc response profile.

Siat1 Δ P1 Animals Are Unable to Express Sia-Fc—When tested in parallel with their WT cohorts in the OVA model of pulmonary allergic inflammation, *Siat1 Δ P1* mice, with an inactivated P1 promoter, were completely unable to express Sia-Fc in their circulatory IgGs, either at base line or after acute or chronic inflammatory challenges (Fig. 2). This is reflected in the SNA/Fc ratios, where values <30 were below the limits of detection (Fig. 2B). However, the inability to express Sia-Fc is




FIGURE 2. Circulatory Fc sialylation in OVA model of allergic pulmonary inflammation. C57BL/6 (WT) and *Siat1*ΔP1 mice were sensitized to OVA and subjected to acute and chronic protocols of pulmonary inflammation as described under "Experimental Procedures." Sera from five animals representing each of the conditions were pooled, and Fc fragments of IgG were isolated from pooled sera from animals sensitized but not challenged by OVA (Primed), challenged with the acute protocol (Acute), and challenged with the chronic protocol (Chron). A, sera were subjected to SDS-PAGE analysis, probed with SNA or ECL (green), anti-Fc antibody (blue), and anti-Fab antibody (red). Resol, resolution. B, quantitation of the data from A expressed as SNA/anti-Fc or ECL/anti-Fc ratios. Ratio values <30 were regarded as random noise.




FIGURE 3. Acute phase response is accompanied by reduced circulatory Sia-Fc. Fc fragments were isolated from the pooled sera of C57BL/6 (WT), *Siat1*ΔP1 (ΔP1), and *Siat1*-null (KO) mice at base line (Rest) or 72 h after elicitation of the acute phase response by subcutaneous injection of turpentine (T72). The samples were separated by SDS-PAGE and probed with SNA (Cy5), anti-Fc antibody (Cy3), and anti-Fab antibody (Cy2). In each lane, serum pools from five animals were used.

not due to limitation in acceptor substrate for ST6Gal-1, as the ECL/Fc ratios indicate an abundance of free galactose termini. Fig. 3 clearly shows the absence of all SNA reactivity in *Siat1*ΔP1 circulatory Fc. Circulatory Fc from *Siat1*-null animals also had the expected lack of Sia-Fc due to a genetic inactivation that rendered impossible all ST6Gal-1-mediated α 2,6-sialylation (18, 23).

However, despite the absence of sialylation in the Fc region, IgGs from *Siat1*ΔP1 animals were not completely deficient in α 2,6-sialylation. Fig. 4A shows the α 2,6-sialylation of intact IgG that contains both Fab and Fc regions. Intact circulatory IgGs from *Siat1*ΔP1 animals had significant albeit reduced SNA signals compared with wild-type IgG (Fig. 4A). However, α 2,6-sialylation was notably absent in the Fc fragments, as shown in Fig. 4B, where the SNA/Fc ratio was below the limits of detection. Another α 2,6-sialic acid lectin, PSL, was used to confirm




FIGURE 4. *Siat1*ΔP1 Fc region is undersialylated. The serum pools of three C57BL/6 (WT), three *Siat1*ΔP1 (ΔP1), and three *Siat1*-null (KO) mice at rest were probed as described in the legends to Figs. 1–3, and the results are expressed as SNA/anti-Fc ratios. A, signal ratio of intact IgG; B, signal ratio of an isolated Fc fragment.

the findings with SNA for the lack of α 2,6-sialylation in the Fc fragment of *Siat1*ΔP1 circulatory IgG, and the results are shown in Fig. 5. Together, these data strongly imply that the *Siat1*ΔP1 animals are specifically unable to sialylate the Fc glycan while retaining the capability to sialylate the Fab glycans. Moreover, the inability to sialylate Fc is not due to the absence of terminal galactose acceptor structures, as visualized by ECL.

Mass Spectrometry Confirmation for Absence of α 2,6-Sia-Fc in *Siat1*ΔP1 IgG—Glycans released from gel-purified Fc fragments of WT and *Siat1*ΔP1 mice were profiled by MALDI-TOF-MS and confirmed by linear ion trap-MS. The summary of this analysis is given in Fig. 6, with the MALDI-TOF spectra presented in supplemental Fig. 1. At base line, Fc glycans exist as biantennary structures; tri- and tetra-antennary structures were not detected. Consistent with published reports (24), 9% of the wild-type Fc glycans terminated with sialic acid, and all Fc glycans were modified by core fucosylation. All sialylated structures were singly sialylated, indicating that only 4.5% of the available nonreducing termini are capped by a sialic acid. 41% of the wild-type Fc glycan termini at base line had an exposed Gal that was not further modified by sialylation. Moreover, the majority of the termini (54%) had an exposed GlcNAc that was not occupied by Gal. The abundance of these precursor termini supports further the idea that Sia-Fc formation has at least two rate-limiting steps: the formation of Gal-GlcNAc from GlcNAc and the sialyl modification by ST6Gal-1 to form Sia-Gal-GlcNAc. MS revealed no sialylated structures in the *Siat1*ΔP1 Fc glycans. Importantly, the distribution between Gal and GlcNAc termini was similar to that in wild-type Fc (42 and 57%, respectively), indicating that the defect in *Siat1*ΔP1 relates only to the sialylation event and not the ability to generate the precursor Gal-GlcNAc structure.

DISCUSSION

When present *in vivo*, sialic acids on Fc glycans exist only in α 2,6-linkages requiring ST6Gal-1. Fc fragments that are artificially forced to acquire α 2,3-sialyl linkages do not have anti-




FIGURE 5. PSL and ECL reactivity of Fc fragments. Fc fragments from serum pools of five C57BL/6 (WT), *Siat1* Δ P1 (Δ P1), and *Siat1*-null (KO) mice were subjected to SDS-PAGE and blotted for reactivity against PSL (A) and ECL (B), recognizing the α 2,6-sialyl type 2 lactosamine and unsialylated type 2 lactosamine structures, respectively, as diagrammed.

		Genotype						
		WT	Δ P1	WT	Δ P1	WT	Δ P1	WT
% Total Glycans	WT	26	53	13	5	4	0	0
	Δ P1	33	49	17	0	0	1	1

▲ Fuc ■ GlcNAc ○ Man ○ Gal ◆ Sia

FIGURE 6. Structural composition of Fc glycans. Shown are the results from linear ion trap-MS analysis for the glycan structural composition (expressed as percent of total glycans) present on the Fc fragments in untreated WT and *Siat1* Δ P1 pooled sera. MALDI-TOF-MS data from which this information was derived are shown in supplemental Fig. 1.

inflammatory activity (10). Here, we confirmed the absolute requirement for functional ST6Gal-1 in the creation of sialic acid linkages on the Fc glycan of circulatory IgG. The *Siat1*-null mouse, with an inactivated ST6Gal-1 gene, does not express Sia-Fc.

Hepatic expression and systemic circulatory levels of ST6Gal-1 are tightly regulated during inflammation (25). Therefore, we hypothesized that the degree of Fc sialylation might likewise be altered during the inflammatory process. To date, the most characterized human conditions that alter circulatory Sia-Fc content are rheumatoid arthritis and pregnancy, which suppress and increase Sia-Fc, respectively (26, 27). Reduction of Fc sialylation upon induction of an antigen-specific immune response has been previously reported (8). We have recapitulated this observation in mouse models upon challenge with the sterile irritant turpentine (Fig. 4) and also in the earliest stages of pulmonary response to acute NThi challenge (Fig. 1). The rationale for decreased Sia-Fc in acute inflammation is not understood, but altered biosynthesis is unlikely to be the sole mechanism due to the rapidity of Sia-Fc disappearance from the circulation, *e.g.* within hours. Another explanation is that existing Sia-Fcs are preferentially bound and removed from the circulation by Sia-Fc-binding cells (*e.g.* sple-

nic macrophages in mice and dendritic cells in humans) responding to inflammatory cues. Concomitantly, Sia-Fc in the circulation may be further diluted by the *de novo* synthesis of antigen-specific Ig with undersialylated Fc to generate a protective response (8). An unexpected observation was that progression from acute to chronic inflammation in our animal models was paralleled by a paradoxical 3-fold increase in Sia-Fc. A possible explanation is that our chronic inflammation models were achieved by forced and repeated exposures to challenge, and the dramatic increase in Sia-Fc might represent a futile attempt to limit destructive inflammation in the face of an unrelenting challenge. Our data suggest that increased Fc sialylation accompanying chronic inflammatory conditions is a two-stage sequential process. A near-term response to an initial challenge is increased production of Gal-terminated Fc glycans. Increased conversion of these Gal termini by ST6Gal-1, *e.g.* to produce Sia-Fc, occurs subsequently upon prolonged and repeated exposure to the challenge. At present, there is no information on whether the increased Gal termini are due to increased branching of core N-glycans or to increased conversion of GlcNAc to Gal-GlcNAc or both. Whatever the case, our data show there is an even greater surplus of Gal termini in the *Siat1* Δ P1 Fc, further supporting the idea that ST6Gal-1-mediated sialylation is the abrogated step in the *Siat1* Δ P1 animals.

Our data also unexpectedly show that inactivation of the P1 promoter of the ST6Gal-1 gene in mice abrogated the ability to express Sia-Fc in circulatory IgG. Because ablation of P1 results only in decreased ST6Gal-1 in the liver and systemic circulation (16, 17), our observation strongly infers a role for circulatory ST6Gal-1, previously considered a functionless byproduct of metabolic inefficiency, in the construction of the sialic acid linkage on the Fc glycans. Reduced circulatory ST6Gal-1 resulting in the lack of Sia-Fc may explain the generally proinflammatory tendencies noted in the *Siat1* Δ P1 mouse (11).

IgG is made in B cells that do not utilize the P1 promoter to express ST6Gal-1 (14), and the precise reason for the requirement of a functional P1 for Sia-Fc formation is unclear. Because P1 ablation dramatically decreases ST6Gal-1 levels in the systemic circulation (16, 17), a tantalizing possibility is that the Fc glycans are sialylated directly by the pool of extracellular or extrinsic ST6Gal-1 in the circulation. An alternative explanation is the existence of clonal populations of B cells with a differential ability to express Sia-Fc, and circulatory ST6Gal-1 influences the clonal selection process for these populations. Thus, *Siat1* Δ P1 mice might lack the particular subset of B cells that produce sialylated Fc glycans. Indeed, circulatory ST6Gal-1 deficiency has been attributed to altered hematopoietic activity in bone marrow (11, 12, 16). IgG acquires anti-inflammatory properties upon Fc sialylation. Differential Fc sialylation may serve as a mechanism in the normal switching between pro- and anti-inflammatory environments. Although IgGs containing Sia-Fc are the effective portions of large-dose IVIG therapy, they typically comprise only 5–10% of the IgGs in human IVIG pools. Enriching for Sia-Fc for a more effective clinical outcome is an issue of current intense interest (28, 29). Elucidating the mechanism by which Sia-Fc is naturally generated will have significant therapeutic value and, at the very least,

illuminate an approach to enhance the proportion of Sia-Fc in IVIG therapy.

Acknowledgments—We thank Christine Collins for excellent technical assistance and Dr. Parastoo Azadi (Complex Carbohydrate Research Center, University of Georgia) for providing glycan analytical services.

REFERENCES

1. Bruhns, P., Samuelsson, A., Pollard, J. W., and Ravetch, J. V. (2003) Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. *Immunity* **18**, 573–581
2. Samuelson, P. (2001) Anticircumvention rules: threat to science. *Science* **293**, 2028–2031
3. Gregoire-Gauthier, J., Durrieu, L., Duval, A., Fontaine, F., Dieng, M. M., Bourgey, M., Patey-Mariaud de Serre, N., Louis, I., and Haddad, E. (2012) Use of immunoglobulins in the prevention of GvHD in a xenogeneic NOD/SCID/ γ c[−] mouse model. *Bone Marrow Transplantation* **47**, 439–450
4. Sokos, D. R., Berger, M., and Lazarus, H. M. (2002) Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. *Biol. Blood Marrow Transplant.* **8**, 117–130
5. Sullivan, K. M., Kopecky, K. J., Jocom, J., Fisher, L., Buckner, C. D., Meyers, J. D., Counts, G. W., Bowden, R. A., Peterson, F. B., and Witherspoon, R. P. (1990) Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. *N. Engl. J. Med.* **323**, 705–712
6. Sullivan, K. M., Storek, J., Kopecky, K. J., Jocom, J., Longton, G., Flowers, M., Siadak, M., Nims, J., Witherspoon, R. P., Anasetti, C., Appelbaum, F. R., Bowden, R. A., Buckner, C. D., Crawford, S. W., Deeg, H. J., Hansen, J. A., McDonald, G. B., Sanders, J. E., and Storb, R. (1996) A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. *Biol. Blood Marrow Transplant.* **2**, 44–53
7. Anthony, R. M., Kobayashi, T., Wermeling, F., and Ravetch, J. V. (2011) Intravenous γ -globulin suppresses inflammation through a novel T_H2 pathway. *Nature* **475**, 110–113
8. Kaneko, Y., Nimmerjahn, F., and Ravetch, J. V. (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. *Science* **313**, 670–673
9. Anthony, R. M., Wermeling, F., Karlsson, M. C., and Ravetch, J. V. (2008) Identification of a receptor required for the anti-inflammatory activity of IVIG. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 19571–19578
10. Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., and Ravetch, J. V. (2008) Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. *Science* **320**, 373–376
11. Nasirikenari, M., Chandrasekaran, E. V., Matta, K. L., Segal, B. H., Bogner, P. N., Lugade, A. A., Thanavala, Y., Lee, J. J., and Lau, J. T. (2010) Altered eosinophil profile in mice with ST6Gal-1 deficiency: an additional role for ST6Gal-1 generated by the P1 promoter in regulating allergic inflammation. *J. Leukoc. Biol.* **87**, 457–466
12. Nasirikenari, M., Segal, B. H., Ostberg, J. R., Urbasic, A., and Lau, J. T. (2006) Altered granulopoietic profile and exaggerated acute neutrophilic inflammation in mice with targeted deficiency in the sialyltransferase ST6Gal-1. *Blood* **108**, 3397–3405
13. Dalziel, M., Huang, R. Y., Dall'Olio, F., Morris, J. R., Taylor-Papadimitriou, J., and Lau, J. T. (2001) Mouse ST6Gal sialyltransferase gene expression during mammary gland lactation. *Glycobiology* **11**, 407–412
14. Wuensch, S. A., Huang, R. Y., Ewing, J., Liang, X., and Lau, J. T. (2000) Murine B cell differentiation is accompanied by programmed expression of multiple novel β -galactoside α 2,6-sialyltransferase mRNA forms. *Glycobiology* **10**, 67–75
15. Hu, Y. P., Dalziel, M., and Lau, J. T. (1997) Murine hepatic β -galactoside α 2,6-sialyltransferase gene expression involves usage of a novel upstream exon region. *Glycoconj. J.* **14**, 407–411
16. Jones, M. B., Nasirikenari, M., Feng, L., Migliore, M. T., Choi, K. S., Kazim, L., and Lau, J. T. (2010) Role for hepatic and circulatory ST6Gal-1 sialyltransferase in regulating myelopoiesis. *J. Biol. Chem.* **285**, 25009–25017
17. Appenheimer, M. M., Huang, R. Y., Chandrasekaran, E. V., Dalziel, M., Hu, Y. P., Soloway, P. D., Wuensch, S. A., Matta, K. L., and Lau, J. T. (2003) Biologic contribution of P1 promoter-mediated expression of ST6Gal-1 sialyltransferase. *Glycobiology* **13**, 591–600
18. Hennet, T., Chui, D., Paulson, J. C., and Marth, J. D. (1998) Immune regulation by the ST6Gal sialyltransferase. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 4504–4509
19. Lugade, A. A., Vethanayagam, R. R., Nasirikenari, M., Bogner, P. N., Segal, B. H., and Thanavala, Y. (2011) Nrf2 regulates chronic lung inflammation and B cell responses to nontypeable *Haemophilus influenzae*. *Am. J. Respir. Cell Mol. Biol.* **45**, 557–565
20. Lugade, A. A., Bogner, P. N., Murphy, T. F., and Thanavala, Y. (2011) The role of TLR2 and bacterial lipoprotein in enhancing airway inflammation and immunity. *Front. Immun.* **2**, 10
21. Lugade, A. A., Bogner, P. N., and Thanavala, Y. (2011) Murine model of chronic respiratory inflammation. *Adv. Exp. Med. Biol.* **780**, 125–141
22. Murphy, T. F. (2003) Respiratory infections caused by nontypeable *Haemophilus influenzae*. *Curr. Opin. Infect. Dis.* **16**, 129–134
23. Martin, L. T., Marth, J. D., Varki, A., and Varki, N. M. (2002) Genetically altered mice with different sialyltransferase deficiencies show tissue-specific alterations in sialylation and sialic acid 9-O-acetylation. *J. Biol. Chem.* **277**, 32930–32938
24. Blomme, B., Van Steenkiste, C., Grassi, P., Haslam, S. M., Dell, A., Callewaert, N., and Van Vlierberghe, H. (2011) Alterations of serum protein N-glycosylation in two mouse models of chronic liver disease are hepatocyte and not B cell-driven. *Am. J. Physiol. Gastrointest. Liver Physiol.* **300**, G833–F842
25. Baumann, H., and Gauldie, J. (1994) The acute phase response. *Immunol. Today* **15**, 74–80
26. Kötz, K., Hänsler, M., Sauer, H., Kaltenhäuser, S., and Häntzschel, H. (1996) Immunoglobulin G galactosylation deficiency determined by isoelectric focusing and lectin affinity blotting in differential diagnosis of rheumatoid arthritis. *Electrophoresis* **17**, 533–534
27. van de Geijn, F. E., Wuhler, M., Selman, M. H., Willemsen, S. P., de Man, Y. A., Deelder, A. M., Hazes, J. M., and Dolhain, R. J. (2009) Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. *Arthritis Res. Ther.* **11**, R193
28. Stadlmann, J., Weber, A., Pabst, M., Anderle, H., Kunert, R., Ehrlich, H. J., Peter Schwarz, H., and Altmann, F. (2009) A close look at human IgG sialylation and subclass distribution after lectin fractionation. *Proteomics* **9**, 4143–4153
29. Stadlmann, J., Pabst, M., and Altmann, F. (2010) Analytical and functional aspects of antibody sialylation. *J. Clin. Immunol.* **30**, Suppl. 1, 15–19